Pfizer Enriches Oncology Franchise Through BioInvent’s TAM Targeting Antibodies
By Jasmine Kalsi
Pharma Deals Review: Vol 2017 Issue 1 (Table of Contents)
Published: 11 Jan-2017
DOI: 10.3833/pdr.v2017.i1.2216 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Strengthening its oncology pipeline, Pfizer signed a deal with Swedish biotech, BioInvent, for the research, development and commercialisation of the latter’s novel tumour-associated myeloid cells (TAM) targeted antibodies...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS